LENSAR (LNSR) AI Stock Analysis

• Market Cap: $152.26M
• Dividend Yield: N/A
• Average Volume (3M): 148.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: 28.24%
• EPS Growth: -334.39%
• Country: US
• Employees: 140
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Devices
• EPS (TTM): -2.32
• Shares Outstanding: 11,904,989
• 10 Day Avg. Volume: 224,050
• 30 Day Avg. Volume: 148,062
• PEG Ratio: 0.19
• Price to Book (P/B): 0.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.01
• Enterprise Value/Market Cap: 0.12
• Enterprise Value/Revenue: 0.09
• Enterprise Value/Gross Profit: 0.67
• Enterprise Value/Ebitda: -0.82
• 1Y Price Target: $15.00
• Price Target Upside: 14.59% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 48 Neutral
• Price Target: $13.00 ▼(-0.69%Downside)

LENSAR's overall score reflects a mix of financial instability and potential corporate growth. Financial challenges are significant, but the merger approval offers a promising strategic opportunity. Technical indicators are neutral, and valuation remains constrained by negative earnings.

Positive Factors

Acquisition

The announced acquisition by Alcon is seen as a positive outcome for both Lensar and Alcon, with Lensar experiencing strong adoption of its ALLY System in the cataract surgery market.

Financial Performance

The company reported Q4 revenue of $16.7M, which was 38% higher than the previous year and above market expectations.

Market Performance

LENSAR's installed base for the ALLY system grew by 86%, suggesting strong demand and expansion potential.

Negative Factors

Growth Challenges

Lensar is required to achieve substantial procedure growth to meet the terms of the acquisition agreement, which may pose challenges.

Profitability

Gross margins are lower due to higher capital sales, which impacts the company's profitability.

Valuation

The stock is rated as Neutral because the implied takeout value is seen as fairly valued, indicating limited upside potential.

LENSAR Business Overview & Revenue Model

Company Description

LENSAR, Inc. (LNSR) is a medical technology company specializing in the development and commercialization of advanced femtosecond laser systems for cataract surgery. Its flagship product, the LENSAR Laser System, is designed to provide precision and accuracy in cataract treatment, enhancing surgical outcomes and patient safety. The company operates within the healthcare sector, focusing on ophthalmology and leveraging cutting-edge technology to address the needs of eye care professionals and their patients.

How the Company Makes Money

LENSAR generates revenue primarily through the sale and leasing of its LENSAR Laser System to ophthalmologists, hospitals, and surgical centers. The company also earns money from service agreements and maintenance contracts associated with its laser systems, ensuring continuous support and operational efficiency for its clients. Additionally, LENSAR may engage in strategic partnerships and collaborations with other companies in the ophthalmic industry to expand its market reach and enhance its technological offerings, contributing to its revenue growth.

LENSAR Financial Statement Overview

Summary

LENSAR is experiencing revenue growth, yet struggles with persistent losses and financial instability. The company's negative equity and continuing operational losses pose significant risks, while cash flow issues reflect ongoing challenges in achieving sustainable financial health. The need for strategic improvements in profitability and balance sheet management is clear.

Income Statement

LENSAR has demonstrated revenue growth, with a TTM increase of approximately 6.68% compared to the previous year. However, the company continues to face profitability challenges, as reflected in negative net profit and EBIT margins, standing at -99.17% and -16.49% respectively for the TTM. The gross profit margin is 47.45%, showing some strength in core operations, but the persistent losses are concerning.

Balance Sheet

The company's financial stability is concerning with a negative stockholders' equity of -$22.14 million, indicating insolvency risk. The debt-to-equity ratio is negative due to negative equity, complicating leverage analysis. The equity ratio is also negative. These factors highlight financial instability, despite manageable total liabilities relative to assets.

Cash Flow

LENSAR's cash flow situation is challenging, with negative free cash flow of -$4.05 million in the TTM and a negative free cash flow growth rate, suggesting cash generation issues. The operating cash flow to net income ratio is 0.069, indicating poor cash conversion of net losses. Continued reliance on financing activities is evident from cash inflows in this segment.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	57.06M	53.49M	42.16M	35.36M	34.46M	26.38M
Gross Profit	27.08M	25.85M	21.11M	19.95M	17.83M	14.07M
EBITDA	-6.63M	-5.97M	-8.71M	-16.77M	-16.89M	-15.87M
Net Income	-56.59M	-31.40M	-14.38M	-19.65M	-19.65M	-21.18M
Balance Sheet
Total Assets	72.96M	66.30M	69.58M	55.84M	66.47M	79.12M
Cash, Cash Equivalents and Short-Term Investments	25.25M	22.45M	24.06M	14.67M	31.64M	40.60M
Total Debt	2.47M	2.61M	2.31M	2.80M	2.80M	3.31M
Total Liabilities	81.32M	61.44M	22.41M	13.86M	11.59M	11.91M
Stockholders Equity	-22.14M	4.86M	47.18M	41.98M	54.88M	67.21M
Cash Flow
Free Cash Flow	-4.05M	-2.43M	-9.89M	-14.97M	-9.32M	-14.16M
Operating Cash Flow	-3.91M	-2.27M	-9.66M	-14.86M	-8.97M	-13.79M
Investing Cash Flow	-404.00K	-2.16M	-4.16M	-115.00K	-354.00K	-326.00K
Financing Cash Flow	9.90M	78.00K	19.76M	-1.99M	361.00K	50.00M

LENSAR Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LNSR, the sentiment is Positive. The current price of 13.09 is above the 20-day moving average (MA) of 12.72, below the 50-day MA of 13.41, and above the 200-day MA of 10.15, indicating a neutral trend. The MACD of -0.16 indicates Negative momentum. The RSI at 53.14 is Neutral, neither overbought nor oversold. The STOCH value of 85.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LNSR.

LENSAR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ELMD	77 Outperform	$182.82M	25.46	16.56%	―	14.85%	64.96%
SGHT	57 Neutral	$210.43M	―	-52.87%	―	-4.16%	12.79%
MYO	53 Neutral	$77.71M	―	-35.68%	―	69.17%	39.01%
CVRX	53 Neutral	$157.48M	―	-76.01%	―	25.62%	11.86%
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
LNSR	48 Neutral	$152.26M	―	-304.05%	―	28.24%	-334.39%
CTSO	46 Neutral	$80.77M	―	-94.65%	―	-5.86%	50.76%

LENSAR Corporate Events

LENSAR Stockholders Approve Merger with Alcon Research

On July 2, 2025, LENSAR, Inc. held a virtual special meeting where stockholders voted on proposals related to a merger agreement with Alcon Research, LLC. The merger proposal, along with a compensation proposal for executives related to the merger, was approved by the requisite vote. The adjournment proposal was deemed unnecessary as there was a quorum present and sufficient proxies to approve the merger proposal.

The most recent analyst rating on (LNSR) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on LENSAR stock, see the LNSR Stock Forecast page.

FTC Extends Waiting Period for LENSAR Merger

On March 23, 2025, LENSAR, Inc. entered into a merger agreement with Alcon Research, LLC, and its subsidiary, VMI Option Merger Sub, Inc., to become a wholly owned subsidiary of Alcon. However, on May 21, 2025, the Federal Trade Commission requested additional information, extending the waiting period for the merger under the Hart-Scott-Rodino Antitrust Improvements Act. LENSAR and Alcon plan to cooperate with the FTC, aiming to complete the merger in the second half of 2025, pending regulatory approval and other conditions.

The most recent analyst rating on (LNSR) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on LENSAR stock, see the LNSR Stock Forecast page.